Antibiotic and anti-inflammatory therapies for cystic fibrosis

James F. Chmiel, Michael W. Konstan, J. Stuart Elborn

Research output: Contribution to journalArticlepeer-review

53 Citations (Scopus)

Abstract

Cystic fibrosis (CF) lung disease is characterized by chronic bacterial infection and an unremitting inflammatory response, which are responsible for most of CF morbidity and mortality. The median expected survival has increased from <6 mo in 1940 to >38 yr now. This dramatic improvement, although not great enough, is due to the development of therapies directed at secondary disease pathologies, especially antibiotics. The importance of developing treatments directed against the vigorous inflammatory response was realized in the 1990s. New therapies directed toward the basic defect are now visible on the horizon. However, the impact of these drugs on downstream pathological consequences is unknown. It is likely that antibiotics and anti-inflammatory drugs will remain an important part of the maintenance regimen for CF in the foreseeable future. Current and future antibiotic and anti-inflammatory therapies for CF are reviewed.

Original languageEnglish
Article numbera009779
Number of pages18
JournalCold Spring Harbor Perspectives in Medicine
Volume3
Early online date23 Jul 2013
DOIs
Publication statusPublished - 2013

ASJC Scopus subject areas

  • General Medicine
  • General Biochemistry,Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Antibiotic and anti-inflammatory therapies for cystic fibrosis'. Together they form a unique fingerprint.

Cite this